Semax is a synthetic heptapeptide — sequence Met-Glu-His-Phe-Pro-Gly-Pro — built from a fragment of the adrenocorticotropic hormone, ACTH(4-10), with an added Pro-Gly-Pro tail. That short C-terminal extension is the key design idea: it slows enzymatic breakdown, giving the molecule far greater stability than the natural ACTH fragment while stripping away the hormone's classic corticotropic activity. Developed in Russia in the 1980s, Semax has since become one of the most-studied regulatory peptides in neurotrophic and neuroprotective research.
What keeps Semax in the literature is not a single dramatic result but the convergence of findings across neurotrophin signaling, neuroprotection and cognition in model systems. This guide summarizes what the peer-reviewed research reports — and, just as importantly, where the human evidence is still thin.
ACTH and its fragments have long been known to influence learning and attention in animal models, but the natural peptides are degraded within minutes. Semax was engineered to keep the behaviorally active ACTH(4-10) core — sometimes written as the ACTH(4-7)PGP motif — while adding the terminal proline-glycine-proline that resists peptidases. The result is a compound that, in the models studied, retains neuromodulatory activity without the adrenal-stimulating effects of the parent hormone. This "keep the signal, remove the hormone" design is why Semax is described in the literature as a regulatory neuropeptide rather than a hormone analog in the therapeutic sense.
The observation that anchors much of the Semax literature comes from neurotrophin research. In a study published in Brain Research (Dolotov et al., 2006), a single administration of Semax was reported to change brain-derived neurotrophic factor (BDNF) and its receptor trkB in the rat hippocampus: BDNF protein rose roughly 1.4-fold, trkB phosphorylation about 1.6-fold, exon-III BDNF mRNA around 3-fold and trkB mRNA about 2-fold, alongside changes in a behavioral learning task.
The important nuance, often lost in marketing copy: this does not establish a human benefit. It means that, in this rodent model, Semax behaved like a modulator of neurotrophic signaling — nudging the BDNF/trkB system, a pathway central to synaptic plasticity, learning and neuronal survival. It looks less like a single-receptor drug and more like an upstream signal that shifts the brain's own repair and plasticity machinery in the systems studied.
Across in-vitro and animal-model studies, Semax has been associated with a range of activities. Each of the following is drawn from laboratory or preclinical research — none should be read as an established human clinical outcome:
Most neuroactive drugs are designed to hit one receptor — a dopamine site, a glutamate channel, a reuptake transporter. Semax is interesting precisely because, in the models studied, it appears to act more diffusely: modulating neurotrophic factors, inflammatory mediators and stress-response genes rather than a single target. Because it derives from an endogenous peptide sequence, researchers often frame it as helping brain tissue lean toward its own protective and plasticity-related programs. This "signal, not switch" behavior is a recurring theme in the Semax literature — and also a reason its full mechanism is still being mapped.
This is the part a responsible sourcing page should state plainly. The preclinical evidence for Semax is genuinely substantial, spanning neurotrophin studies, cerebral-ischemia models and behavioral experiments accumulated over several decades, largely from Russian research groups.
However, independent, large-scale human clinical trials outside Russia remain limited. In Russia, Semax is registered for certain clinical uses, but much of that evidence has not been reproduced in the broad international trial literature. A great deal of the interest in Semax comes from mechanistic and animal work; confirming which of those effects translate to robust, generalizable human outcomes — and under what conditions — is an area of ongoing research, not settled fact. Treating preclinical findings as proven human benefits is exactly the mistake this field is prone to, and we won't make it here.
Semax is not FDA-approved in the United States for any use and is not an approved drug. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed Semax — together with several other peptides — for possible inclusion on the Section 503A bulk drug substances list used in pharmacy compounding. According to FDA briefing materials and reporting on the meeting, agency staff recommended against adding the reviewed substances, citing gaps in characterization, effectiveness and safety data. That review does not make Semax an approved therapy; the compounds discussed on this page are offered strictly as research chemicals for laboratory use.
For research applications, identity and purity are what separate a usable reference compound from an unknown. The Semax we supply to the research community is a lyophilized powder tested to high purity by HPLC, with a third-party Certificate of Analysis (COA) available for each lot, strictly for in-vitro laboratory use:
New to handling lyophilized peptides? See our Research Center for storage, reconstitution and COA guidance.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on a fragment of the adrenocorticotropic hormone, ACTH(4-10), joined to a Pro-Gly-Pro tail that improves stability. It was developed in Russia and is one of the most-studied regulatory peptides in neurotrophic and neuroprotective research.
In laboratory and animal studies Semax has been reported to modulate neurotrophic signaling rather than acting on a single classical receptor. Published research observed increases in brain-derived neurotrophic factor (BDNF) and its receptor trkB in the rat hippocampus, alongside effects on inflammation and cell-death pathways in cerebral-ischemia models.
No. Semax sold for laboratory research is strictly for in-vitro and analytical use. It is not FDA-approved in the United States, is not a drug, and is not approved for human or animal use. In July 2026 an FDA advisory committee reviewed Semax among several peptides for a compounding bulk-substances list, and FDA staff recommended against inclusion, citing gaps in characterization, effectiveness and safety data.
Most controlled evidence comes from research conducted in Russia, where Semax is registered for certain clinical uses. Large, independent human clinical trials outside Russia remain limited, and much of the mechanistic support comes from cell and animal models rather than broad international clinical data.